

DAFTAR PUSTAKA

- Abbas, A.K., Aster, J.C., dan Kumar, V., 2013, *Robbins Basic Pathology, Edisi 9*, Singapura: Elsevier Saunders.
- Al-Bader M., Al-Saji S., Ford C.H.J, Francis I., and Al-Ayadhy B., 2010, “Real-Time PCR: Detection of Oestrogen Receptor-Alpha and -Beta Isoforms and Variants in Breast Cancer”, *Anticancer research*, 30, 4147-56.
- Bae S.Y., Kim S., Lee J.H., Lee H., Lee S.K., Kil W.H., Kim S.W., Lee J.E., and Nam S.J., 2015, “Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer”, *BMC Cancer*, 15, 138.
- Baek, J-M., Chae B-J., Song B-J., Jung S-S, 2015, “The potensial role of estrogen receptor β 2 in breast cancer”, *International Journal of Surgery*, 14, 17-22.
- Bardin A., Boulle N., Lazennec G., Vignon F., Pujol P., 2004, “Loss of ER β expression as a common step in estrogen-dependent tumor progression”, *Endocrine-Related Cancer*, 11, 537–51.
- BieÁche I., Parfait B., Laurendeau I., Girault I., Vidaud M., and Lidereau R., 2001, “Quantification of estrogen receptor α and β expression in sporadic breast cancer”, *Oncogene*, 20, 8109 -815.
- Biganzoli L., 2009, “Prognostic and Predictive Factors”, *Cancer Treatment and Research*, 16, 13-30.
- Cianfrocca M., Goldstein L.J., 2004, “Prognostic and Predictive Factors in Early-Stage Breast Cancer”, *The Oncologist*. 9, 606-16.
- Corwin, E.J., 2000, *Buku saku patofisiologi*, Jakarta: ECG.
- Dent R., Trudeau M., Pritchard K.I., Wedad M. Hanna W.M., Kahn K.H., Sawka C.A., Lickley L.A., Ellen Rawlinson E., Sun P., and Narod S.A., 2007, “Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence”, *Clin Cancer Res*, 13, 15.
- Deroo B.J. and Korach K.S., 2006, “Estrogen receptors and human disease”, *The Journal of Clinical Investigation*, 116, 3.
- Fielding, L.P., Henson, D.E., 1992, “Multiple prognostic factors and outcome analysis in patient with cancer”, *Cancer*, 71, 2426–29.

- Fisher B., Bauer M., and Wickerham D.L., 1983, "Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update", *American Cancer Society*, 52, 1551–57.
- Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., Ruby S.G., O'Malley F., Simpson J.F., Connolly J.L., Hayes D.F., Edge S.B., Lichter A., and Schnitt S.J., 2000, "Prognostic Factors in Breast Cancer. *Archives of Pathology & Laboratory Medicine*", 124, 966-78.
- Garne, J.P., Aspegren, K., Linell F., Rank F., Ranstam J., 1994, "Primary prognostic factors in invasive breast cancer with special reference to ductal carcinoma and histologic malignancy grade", *Cancer*, 73, 1438 –48.
- Globocan, 2012, *Cervical Cancer, Estimated Incidence, mortality and prevalence Worldwide in 2012* (internet), Section of Cancer surveillance, <<http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp>>(diakses 8 Oktober 2017).
- Gustafsson J., 1999, "Estrogen receptor β – a new dimension in estrogen mechanism of action", *Journal of Endocrinology*, 163, 379–83.
- Hall D.C., 2001, "Nutritional Influences on Estrogen Metabolism", *Applied nutritional science report*, 1, 1-8.
- Hayashi S-I., Eguchi H., Tanimoto K., Yoshida T., Omoto Y., Inoue A., Yosida N., and Yamaguchi Y., 2003, "The expression and function of estrogen receptor α and β in human breast cancer and its clinical application", 10, 193–202
- Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Ström A., Treuter E., Warner M., and Gustafsson J., 2007, "Estrogen Receptors: How Do They Signal and What Are Their Targets", *Physiol Rev*, 87, 905–31.
- Herynk M.H. and Fuqua S.A., 2004, "Estrogen Receptor Mutations in Human Disease", *Endocrine Reviews*, 25, 869.
- Hou Y., Yuan S., Li H., Wu J., Lu J., Liu G., Lu L., Shen Z., Ding J., and Shao Z., 2004, "ER β exerts multiple stimulative effects on human breast carcinoma cells", *Oncogene*, 23, 5799–5806.

- Honma N., Horii R., Iwase T., Saji S., Younes M., Takubo K., 2008, “Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy”, *J Clin Oncol*, 26, 3727–34
- Huang B., Omoto Y., Yamashita H., Tomaya T., Coombes R.C., Filipovic A., Warner M., Gustafsson J., 2014, “Differential expression of estrogen receptor α , β 1, and β 2 in lobular and ductal breast cancer”, *PNAS*, 111, 1933-38.
- Kementrian Kesehatan Republik Indonesia, 2015, Buletin jendela data & informasi kesehatan: situasi penyakit kanker, kementrian Kesehatan Republik Indonesia, 1, 7-15.
- Kumar N., Mukherjee S., 2013, “Correlation of Various Prognostic Factors in Breast Cancer”, *International Journal of Scientific and Research Publications*, 3, 1-4.
- Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., van de Vijver M.J, 2012, *WHO Classification of Tumours of the breast*, France: IARC Press Lyon, 14-29.
- Lazennec G., Bresson D., Lucas A, Chauveau C., Vignon F., 2001, “ER β inhibits proliferation and invasion of breast cancer cells”, *Endocrinology* 14, 4120–30.
- Lee M., Ho S., Tarapore P., Chung I., and Leung Y., 2013, “Estrogen Receptor β Isoform 5 Confers Sensitivity of Breast Cancer Cell Lines to Chemotherapeutic Agent-Induced Apoptosis through Interaction with Bcl2L12”, *Neoplasia*, 15, 1262–71.
- Leung Y., Lee M., Lam H., Tarapore P., and Ho S., 2012, “Estrogen receptor-beta and breast cancer: Translating biology into clinical practice”, *Steroids*, 77, 727–37.
- Matthews J. and Gustafsson J., 2003, “Estrogen Signaling: A Subtle Balance Between ER α and ER β ”, *Molecular interventions*, 3, 281-92.
- Murdoch F.E. and Gorski J., 1991, “The role of ligand in estrogen receptor regulation of gene expression”, *Molecular and Cellular Endocrinology*, 78, 103-8.
- Murillo-Ortiz B., Pérez-Luque E., Malacara J. M., Daza-Benítez L., Hernández-González M., and Benítez-Bribiesca L., 2008, “Expression of Estrogen Receptor Alpha and Beta in Breast Cancers of Pre- and Post-menopausal Women”, *Pathol. Oncol.Res*, 14, 435–42.

- Murray, R.K., Granner, D.K., Mayes, P.A., dan Rodwell, V.W., *Biokimia Harper*, Edisi 26, Jakarta: Penerbit Buku Kedokteran EGC, 445 & 455.
- Novelli F., Milella M., Melucci E., Benedetto A.D., Sperduti I., Perrone-Donnorso R., Perracchio L., Venturo I., Nisticò C., Fabi A., Buglioni S., Natali P.G., and Mottolese M., 2008, “A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study”, *Breast Cancer Research*, 10, 1-12.
- O’Donnel L., Robertson K.M., Jones M.E., and Simpson E.R., 2001, “Estrogen and Spermatogenesis”, *Endocrine Reviews*, 22, 289–318.
- Oueslati M., Bittaieb I., Sassi N., Jemma A.B., Rahal K., and Oueslati R., 2017, “ER α and ER β co-expression: An indicator of aggressive tumors and hormonal sensitivity”, *Oncology letters*, 14, 1675-82.
- Pelletier G., and El-Alfy M., 2000, “Immunocytochemical Localization of Estrogen Receptors α and β in the Human Reproductive Organs”, *The Journal of Clinical Endocrinology & Metabolism*, 85, 4835-40.
- Quzwain F., dan Suryawati B., 2017, Correlation between Immunoexpression of ER- α , ER- β , and PR and Grading in Phyllodes Tumour of the Breast, *Jurnal Kedokteran Brawijaya*, 29, 93-103.
- Rakha E. A., Soria D., Green A. R., Lemetre C. , Powe D. G., Nolan C. C., Garibaldi J. M., Ball G., and Ellis I.O., 2014, Nottingham Prognostic Index Plus (NPI +): a modern clinical decision making tool in breast cancer:, *British Journal of Cancer*, 110, 1688–97.
- Rosin G., Boniface J.D., Karthik G.M., Frisell J., Bergh J., and Hartman J., 2014, “Oestrogen receptors b1 and bcx have divergent roles in breast cancer survival and lymph node metastasis”, *British Journal of Cancer*, 111, 918–926.
- Roy S.S and Vadlamudi R.K., 2012, “Role of Estrogen Receptor Signaling in Breast Cancer Metastasis”, *Hindawi Publishing Corporation International Journal of Breast Cancer*, 2012, 1-8.
- Saunders PTK., Millar MR., Williams K., Macpherson S., Bayne C., O’Sullivan C., Anderson TJ., Groome NP., and Miller WR., 2002, “Expression of oestrogen

receptor beta (ERb1) protein in human breast cancer biopsies”, *British Journal of Cancer*, 86, 250-56.

Speirs V., Parkes A.T., Kerin M.J., Walton D.S., Carleton P.J., Fox J.N., and Atkin S.L., 1999, “Coexpression of estrogen receptor alpha and beta: Poor prognostic factors in human breast cancer?”, *Cancer Res*, 59, 525-28.

Stankov A., Bargallo-Rocha J.E., Silvio A.N., Ramirez M.T., Stankova-Ninova K., Meneses-Garcia A., 2012, “Prognostic Factors and Recurrence in Breast Cancer: Experience at the National Cancer Institute of Mexico”, *ISRN Oncology*, 2012, 1-7.

Youlden D., Cramb S., Yip C., Baade P., 2014, “Incidence and mortality of female breast cancer in the Asia Pacific region”, *Cancer Biol Med*, 11, 101-15.

Zahoor S., Haji A., Azhar Battoo, Mariya Qurieshi1 , Wahid Mir, Mudasir Shah, 2017, “Sentinel Lymph Node Biopsy in Breast Cancer: A Clinical Review and Update”, *J breast cancer*, 20, 217-77.

Zhao C., Dahlman-Wright K., and Gustafsson J., 2008, “Estrogen receptor β : an overview and update”, *Nuclear Receptor Signaling*, 6, 1-10.